>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:

  • ACB +22%, RETA +19%, CGC +8.9%, MIC +7.8%, EBIX +7.5%, ICPT +6.6%, BRK.B +5.5%, MCD +4.8%, BCOR +4.7%, PLUG +2.7%, TGNA +2.5%, GOGO +2.3%, ITCI +2.2%, RDNT +2%, ALE +2%, BKI +2%

Select ETFs showing strength:

  • XLE +11.8%, IWM +7.4%, XLI +7.3%, XLF +6.7%, DIA +5.4%, XLB +5.2%, SPY +4.3%, XLV +3.4%, XLK +1.2%, . 

Other news:

  • CALT +50.9% (reports topline results from pivotal Phase 3 NefIgArd trial met primary endpoint)
  • BNTX +23.4% (Pfizer and BioNTech announce vaccine candidate against COVID-19 achieved success in first interim analysis from Phase 3 study)
  • PFE +12.4% (Pfizer and BioNTech (BNTX) announce vaccine candidate against COVID-19 achieved success in first interim analysis from Phase 3 study)
  • FFIV +10.8% (announces $1 bln in total share repurchases across fiscal years 2021 and 2022 and intention to return 50% of free cash flow thereafter; details long term targets)
  • CNTG +7.3% (Centogene and Fujirebio Europe enter partnership to provide rapid and high-quality preventive SARS-CoV-2 Antigen Testing)
  • ARCO +5.5% (released letter with shareholder updates)
  • CMPS +4.9% (joins the Psychiatry Consortium in a collaboration to accelerate drug discovery in mental health care)
  • LMNL +4.1% (reports PDUFA date extended by FDA from March 5, 2021 to June 5)
  • GPRO +3.4% (D.E. Shaw increased passive stake to 5.0%)
  • GSK +2.9% (GlaxoSmithKline and Pfizer report their ViiV Healthcare investigational injectable cabotegravir is superior to oral standard of care for HIV prevention in women)
  • TSN +2% (Tyson Foods announced the European launch of its plant-based protein brand, Raised & Rooted) . 

Analyst comments:

  • FTI +15.5% (upgraded to Buy from Hold at HSBC Securities)
  • JWN +15.2% (upgraded to Outperform from Market Perform at Telsey Advisory Group)
  • RDS.A +11.2% (upgraded to Buy from Hold at HSBC Securities)
  • CAKE +11.1% (upgraded to Buy from Hold at Deutsche Bank)
  • LTHM +8.1% (upgraded to Buy from Neutral at Citigroup)
  • ARQT +6.8% (upgraded to Buy from Neutral at Goldman)
  • TCS +5.1% (upgraded to Neutral from Sell at Goldman)
  • YELP +4.9% (upgraded to Neutral from Sell at UBS)
  • RPRX +4.7% (upgraded to Buy from Neutral at UBS)
  • SNDR +4.1% (upgraded to Buy from Hold at Stifel)
  • VSTO +3.8% (upgraded to Overweight from Sector Weight at KeyBanc Capital Markets)